ASH 2022

Questions discussed in this category

What's the role of ibrutinib and venetoclax in CLL in light of data emerging from ASH 2022?

1 Answer available

What are your top takeaways from ASH 2022?

8 Answers available

Papers discussed in this category

N Engl J Med, 2022 Dec 11

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Lancet Oncol,

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.

Blood Adv, 2022 Jun 14

Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.

J Clin Oncol, 2021 Oct 07

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.

Related Topics